{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}],"title":"Complete Response"},{"measurements":[{"groupId":"OG000","value":"8"}],"title":"Partial Response"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Minor Response"},{"measurements":[{"groupId":"OG000","value":"16"}],"title":"Stable Disease"},{"measurements":[{"groupId":"OG000","value":"12"}],"title":"Progression"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"}],"units":"Participants"}],"description":"Patients were assessed using the Cheson et al. Revised Response Criteria for Malignant Lymphoma (Cheson, et al 2007). A Complete Response (CR) was defined as the disappearance of all evidence of disease, no palpable nodules and bone marrow cleared on biopsy. A Partial Response (PR) was defined as regression of measureable disease and no new sites, with a 50% decrease in sum of the products of dimension (SPD) of nodal masses, and no increase in spleen or liver size. Patients with Waldenstrom's Macroglobulinemia were eligible to be evaluated as a Minor Response (MR) in which a reduction between 25% and 50% of serum monoclonal IgM was observed. A Progression (PD) was defined as having any new lesions or a 50% increase in the SPD of any previously involved nodes. A Stable Disease (SD) is the absence of any of the previously defined responses.","groups":[{"description":"Patients receive 5 mg oral everolimus once daily and 10 mg oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Dose Level 0"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All patients that were registered and treated at Dose Level 0 were pooled and included in this endpoint. 9 patients in Phase I and 32 patients in Phase II were treated and evaluable for this endpoint","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Best Response to Dose Level 0","type":"PRIMARY","unitOfMeasure":"Participants"}